https://finance.yahoo.com/news/mymetics-data-regarding-cold-chain-133500521.html EPALINGES, SWITZERLAND / ACCESSWIRE / October 11, 2018 / Mymetics Corporation (MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announces that new data will be presented by Mymetics' partner, Upperton Ltd., at the American Association of Pharmaceutical Scientists Annual Meeting in Washington, D.C., on November 5th-7th, 2018. Since 2015, Mymetics has been leading a consortium to develop thermostable and cold-chain independent virosome-based vaccines.
https://finance.yahoo.com/news/mymetics-starts-research-collaboration-project-060000475.html EPALINGES, SWITZERLAND / ACCESSWIRE / October 16, 2018 / Mymetics Corporation (MYMX), a pioneer and leader in the research and development of virosome-based vaccines, announced today that Mymetics BV, the Dutch subsidiary of Mymetics Corporation, has entered into a research collaboration project with eTheRNA immunotherapy NV, a clinical stage biotech company developing novel mRNA cancer immunotherapies. The objective of the project is to evaluate the suitability of Mymetics' proprietary virosome vaccine delivery technology in combination with eTheRNA's proprietary TriMix mRNA.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.